NAS:SYNH (USA) Also trade in: Germany

Syneos Health Inc

$ 48.21 0 (0%)
Volume: 274,636 Avg Vol (1m): 548,304
Market Cap $: 5.00 Bil Enterprise Value $: 7.72 Bil
P/E (TTM): 267.80 P/B: 1.75
Earnings Power Value -6.15
Net Current Asset Value -30.39
Tangible Book -25.18
Projected FCF 33.42
Median P/S Value 64.21
Graham Number 0
Peter Lynch Value 2.25
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 4.5/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.04
Cash-To-Debt range over the past 10 years
Min: 0.04, Med: 0.18, Max: 0.37
Current: 0.04
0.04
0.37
Equity-to-Asset 0.38
Equity-to-Asset range over the past 10 years
Min: 0.18, Med: 0.26, Max: 0.42
Current: 0.38
0.18
0.42
Debt-to-Equity 1.00
Debt-to-Equity range over the past 10 years
Min: 0.99, Med: 1.47, Max: 2.31
Current: 1
0.99
2.31
Debt-to-EBITDA 5.99
Debt-to-EBITDA range over the past 10 years
Min: 2.42, Med: 6.13, Max: 22.82
Current: 5.99
2.42
22.82
Interest Coverage 2.10
Interest Coverage range over the past 10 years
Min: 0.03, Med: 2.08, Max: 14.27
Current: 2.1
0.03
14.27
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.30
DISTRESS
GREY
SAFE
Beneish M-Score -2.40
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 1.33%
WACC 7.8%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 6.31
Operating Margin range over the past 10 years
Min: -0.31, Med: 5.97, Max: 11.41
Current: 6.31
-0.31
11.41
Net Margin % 0.42
Net Margin range over the past 10 years
Min: -9.08, Med: -3.08, Max: 8.37
Current: 0.42
-9.08
8.37
ROE % 0.66
ROE range over the past 10 years
Min: -37.63, Med: -8.14, Max: 43.41
Current: 0.66
-37.63
43.41
ROA % 0.26
ROA range over the past 10 years
Min: -9.4, Med: -1.9, Max: 9.54
Current: 0.26
-9.4
9.54
ROC (Joel Greenblatt) % 117.54
ROC (Joel Greenblatt) range over the past 10 years
Min: -154.57, Med: 72.45, Max: 331.19
Current: 117.54
-154.57
331.19
3-Year Total Revenue Growth Rate 46.40
3-Year Revenue Growth Rate range over the past 10 years
Min: 11.8, Med: 17.3, Max: 21.7
Current: 21.7
11.8
21.7
3-Year Total EBITDA Growth Rate 31.60
3-Year EBITDA Growth Rate range over the past 10 years
Min: 5.7, Med: 29.4, Max: 56.1
Current: 9.4
5.7
56.1
3-Year EPS w/o NRI Growth Rate -51.00
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: 0, Max: -51
Current: -51
0
-51

» SYNH's 30-Y Financials

Financials (Next Earnings Date: 2019-08-06)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SYNH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 541714    SIC : 8731
Compare MIL:DIA NAS:GH SHSE:603658 NAS:BRKR SZSE:300676 NAS:PRAH NAS:NEOG NYSE:CRL NAS:QDEL NAS:ICLR NAS:GHDX SHSE:603882 NAS:MYGN BSP:DASA3 NAS:MEDP XPAR:ERF NAS:NEO NYSE:NVTA SZSE:300463 NAS:BEAT
Traded in other countries 8IN.Germany
Address 3201 Beechleaf Court, Suite 600, Raleigh, NC, USA, 27604-1547
Syneos is a global contract research and commercialization organization that provides services to pharmaceutical and biotechnology companies. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Ratios

Current vs industry vs history
PE Ratio (TTM) 267.80
PE Ratio range over the past 10 years
Min: 18.52, Med: 34.41, Max: 3459
Current: 267.8
18.52
3459
Forward PE Ratio 15.43
N/A
PE Ratio without NRI 267.80
PE without NRI range over the past 10 years
Min: 18.52, Med: 34.41, Max: 3459
Current: 267.8
18.52
3459
Price-to-Owner-Earnings 17.21
Price-to-Owner-Earnings range over the past 10 years
Min: 14.64, Med: 22.39, Max: 103.75
Current: 17.21
14.64
103.75
PB Ratio 1.75
PB Ratio range over the past 10 years
Min: 1.2, Med: 5.06, Max: 12.19
Current: 1.75
1.2
12.19
PS Ratio 1.18
PS Ratio range over the past 10 years
Min: 0.91, Med: 1.51, Max: 2.29
Current: 1.18
0.91
2.29
Price-to-Free-Cash-Flow 17.38
Price-to-Free-Cash-Flow range over the past 10 years
Min: 11.26, Med: 19.47, Max: 125.14
Current: 17.38
11.26
125.14
Price-to-Operating-Cash-Flow 15.09
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 9.11, Med: 16.43, Max: 46.11
Current: 15.09
9.11
46.11
EV-to-EBIT 37.67
EV-to-EBIT range over the past 10 years
Min: -574.5, Med: 22.5, Max: 81
Current: 37.67
-574.5
81
EV-to-EBITDA 16.28
EV-to-EBITDA range over the past 10 years
Min: 12.2, Med: 19.3, Max: 80.3
Current: 16.28
12.2
80.3
EV-to-Revenue 1.78
EV-to-Revenue range over the past 10 years
Min: 1.4, Med: 2, Max: 3.9
Current: 1.78
1.4
3.9
PEG Ratio 17.20
PEG Ratio range over the past 10 years
Min: 11.48, Med: 18.67, Max: 23.22
Current: 17.2
11.48
23.22
Current Ratio 1.02
Current Ratio range over the past 10 years
Min: 0.89, Med: 1.12, Max: 1.27
Current: 1.02
0.89
1.27
Quick Ratio 1.02
Quick Ratio range over the past 10 years
Min: 0.89, Med: 1.12, Max: 1.27
Current: 1.02
0.89
1.27
Days Sales Outstanding 59.35
Days Sales Outstanding range over the past 10 years
Min: 40.34, Med: 47.55, Max: 87.83
Current: 59.35
40.34
87.83
Days Payable 9.89
Days Payable range over the past 10 years
Min: 4.52, Med: 8, Max: 10.48
Current: 9.89
4.52
10.48

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -24.80
3-Year Share Buyback Rate range over the past 10 years
Min: -24.8, Med: -5.5, Max: -1
Current: -24.8
-24.8
-1

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.44
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.22, Med: 1.39, Max: 1.55
Current: 1.44
1.22
1.55
Price-to-Median-PS-Value 0.75
Price-to-Median-PS-Value range over the past 10 years
Min: 0.62, Med: 1.01, Max: 1.37
Current: 0.75
0.62
1.37
Price-to-Peter-Lynch-Fair-Value 21.43
Price-to-Peter-Lynch-Fair-Value range over the past 10 years
Min: 11.92, Med: 17.46, Max: 23
Current: 21.43
11.92
23
Earnings Yield (Joel Greenblatt) % 2.68
Earnings Yield (Greenblatt) range over the past 10 years
Min: -1.3, Med: 2.6, Max: 5.9
Current: 2.68
-1.3
5.9
Forward Rate of Return (Yacktman) % 16.50
Forward Rate of Return range over the past 10 years
Min: 16.4, Med: 17.35, Max: 19.9
Current: 16.5
16.4
19.9

More Statistics

Revenue (TTM) (Mil) $ 4,451.93
EPS (TTM) $ 0.18
Beta 1.5
Volatility % 61.42
52-Week Range $ 36.27 - 56.34
Shares Outstanding (Mil) 103.76

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy Y
Higher Gross Margin yoy N
Higher Asset Turnover yoy N